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CytokineFumarate-containing pharmaceuticals are potent therapeutic agents that inﬂuence multiple cellular pathways.
Despite proven clinical efﬁcacy, there is a signiﬁcant lack of data that directly deﬁnes themolecular mechanisms
of action of related, yet distinct fumarate compounds.We systematically compared the impact of dimethyl fuma-
rate (DMF), monomethyl fumarate (MMF) and a mixture of monoethyl fumarate salts (Ca++, Mg++, Zn++;
MEF) on deﬁned cellular responses. We demonstrate that DMF inhibited NF-κB-driven cytokine production
and nuclear translocation of p65 and p52 in an Nrf2-independent manner. Equivalent doses of MMF and MEF
did not affect NF-κB signaling. These results highlight a key difference in the biological impact of related, yet dis-
tinct fumarate compounds.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fumarate esters, and particularly dimethyl fumarate (DMF), are ap-
proved therapeutics for the treatment of two major autoimmune pa-
thologies — multiple sclerosis (MS) and psoriasis. Delayed-release
DMF (also known as gastro-resistant DMF) is an approved oral thera-
peutic for the treatment of MS (Fox, 2012; Gold et al., 2012b; Kappos
et al., 2008, 2012; Linker et al., 2011; MacManus et al., 2011). A mixture
of DMF and three salt conjugates (Ca++, Mg++, and Zn++) of
monoethyl fumarate (MEF) (Hoefnagel et al., 2003) is an approved
oral therapy for the treatment of psoriasis. Despite the demonstrable
safety and efﬁcacy of these therapeutics, the molecular mechanisms
that underlie their efﬁcacy have not been fully deﬁned. Mechanism of
action studies of the various fumarate esters [Table 1] have character-
ized anti-inﬂammatory, cytoprotective, and immunomodulatory prop-
erties (Fox et al., 2014; Linker and Gold, 2013; Linker et al., 2008;
Moharregh-Khiabani et al., 2009;Mrowietz andAsadullah, 2005). How-
ever, the unique and differential effects of these individual fumarate es-
ters, as well as the major metabolite of DMF, monomethyl fumarate
(MMF), remain largely unstudied.
The majority of orally delivered DMF is rapidly metabolized to MMF
by esterases in the intestine (Dibbert et al., 2013; Litjens et al., 2004c;. This is an open access article underWerdenberg et al., 2003). Some DMF forms long-lived glutathione con-
jugates (Dibbert et al., 2013; Ghashghaeinia et al., 2010; Lehmann et al.,
2007; Nelson et al., 1999; Rostami Yazdi and Mrowietz, 2008;
Rostami-Yazdi et al., 2009; Schmidt and Dringen, 2010; Schmidt et al.,
2007; Spencer et al., 1990). It is not clear precisely which cell popula-
tions and the degree to which different immunological compartments
are directly exposed to signiﬁcant levels of DMF or which cell popula-
tions and compartments are exposed exclusively to MMF and/or DMF-
glutathione conjugates. Many preclinical studies have treated DMF
and MMF as interchangeable, and not as two structurally related but
distinct compounds. Although there have been fewer studies on the
pharmacokinetic and pharmacodynamic properties of the MEF mixture
as compared to DMF and MMF, the exposure levels of MEF and half-life
in plasma are far more similar to those of MMF than DMF (Rostami-
Yazdi et al., 2010).
There remains a signiﬁcant lack of data that directly compares and
deﬁnes the molecular mechanisms of action for these related yet dis-
tinct fumarate compounds and their contribution to the therapeutic ef-
fects of the pharmaceuticals that deliver them. The majority of in vitro
and in vivo pre-clinical research has been conducted with DMF. In
vivo, numerous studies have reported that DMF reduces the severity
of experimental autoimmune encephalomyelitis (EAE), a mouse
model of MS (Chen et al., 2014; Fox et al., 2014; Ghashghaeinia et al.,
2010; Ghoreschi et al., 2011; Linker et al., 2011; Reick et al., 2014;
Schilling et al., 2006). Four mechanisms of action have been described.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Chemical structures of fumarates tested.
Compound Molecular formula Molecular weight Structure
DMF C6H8O4 144.13
MMF C5H6O4 130.10
MEF C6H8O4 144.13
MEF-calcium C12H14CaO8 326.31
MEF-zinc C12H14O8Zn 351.62
MEF-magnesium C12H14MgO8 310.54
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via activation of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-
dependent anti-oxidant response pathway (Gold et al., 2012b; Linker
et al., 2011; Scannevin et al., 2012;Wilms et al., 2010). Second, DMF in-
hibits nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB)-driven processes (Gerdes et al., 2007; Ghoreschi et al., 2011;
Litjens et al., 2004b; Loewe et al., 2001, 2002; Moharregh-Khiabani
et al., 2009; Mrowietz and Asadullah, 2005; Peng et al., 2012;
Rostami-Yazdi and Mrowietz, 2008; Vandermeeren et al., 1997, 2001),
resulting in downstream reduction in inﬂammatory cytokine produc-
tion, altered maturation and function of antigen-presenting cells, and
immune deviation of T helper cells (Th) from the Th1 and Th17 proﬁle
to a Th2 phenotype (Ghoreschi et al., 2011; Litjens et al., 2006; Moed
et al., 2004; Peng et al., 2012; Peterson et al., 1998). Third, as anα, β car-
boxylic acid ester, DMF can bind thiol groups andmodulate glutathione
availability and production, which impacts cellular responses to oxida-
tive stress (Dibbert et al., 2013; Lehmann et al., 2007; Murphy et al.,
2001; Nelson et al., 1999; Peterson et al., 1998; Rostami-Yazdi and
Mrowietz, 2008; Rostami-Yazdi et al., 2009; Scannevin et al., 2012;
Schmidt and Dringen, 2010; Schmidt et al., 2007; Spencer et al., 1990).
Fourth, agonism of G-protein coupled receptor 109A (GPR109A, also
known as the hydroxycarboxylic acid receptor 2 (HCA2)) by DMF and
MMF reduces neutrophil adhesion, migration, and recruitment to the
CNS during EAE (Chen et al., 2014; Digby et al., 2012; Hanson et al.,
2010, 2012; Rahman et al., 2014; Tang et al., 2008). The protective effect
of DMF in EAE was mostly lost in HCA2-deﬁcient mice (Chen et al.,
2014).
While DMF has been the primary fumarate used inmostmechanism
of action studies, it has been assumed that MMF, as the primary in vivo
metabolite, mediates all the mechanistic effects of DMF. However, the
relationship between the mechanisms of action of DMF and MMF may
not be so simple. For example, DMF but not MMFwas shown to protect
primary cortical cultures from oxidative glutamate toxicity (Albrecht
et al., 2012). In another study, DMF was shown to be more potent
thanMMF in inducingNrf2 activation (Scannevin et al., 2012). These ex-
amples challenge the assumption that DMF and MMF have identical
function. As previously mentioned, much less is known about theimpact of the MEF mixture or the individual MEF salts on these biolog-
ical processes. Despite reported similarities, a direct assessment on the
effect and potency of DMF, MMF, and MEF has not been performed.
Given the clinical efﬁcacy and safety of delayed-releaseDMF (Foxet al.,
2012; Gold et al., 2012a) in treating MS and a mixture of DMF and MEF
salts (Mrowietz andAsadullah, 2005; Roll et al., 2007) in treatingpsoriasis,
there is signiﬁcant interest in developing next-generation fumarate com-
pounds and expanding the use of fumarates to new clinical indications
where the multi-faceted mechanism of action may provide clinical bene-
ﬁt. Thus, this studywas designed to systematically assess and compare the
ability of various fumarates to modulate deﬁned cellular responses.
2. Materials and methods
2.1. Screening in BioMAP model systems
2.1.1. BioMAP assays
DMF and MMF were evaluated over a range of concentrations in a
panel of in vitro systems to generate compound activity proﬁles using
the BioMAP® platform (assays and analysis provided by BioSeek, Inc.)
as described (Berg et al., 2010; Kunkel et al., 2004a,b). Compounds were
tested at the indicated concentrations (DMF: 0.617, 1.852, 5.556, 16.7,
50, and 150 μM; MMF: 1.852, 5.556, 16.7, 50, 150 and 450 μM). Com-
pounds were prepared in the solvent (DMSO) as directed, added 1 h be-
fore stimulation of the cells, and were present during the whole 24 hour
stimulation period. The ﬁnal concentration of solvent was 0.1% or less.
2.1.2. Data analysis
BioMAP® proﬁles generated for DMF and MMF at nontoxic concen-
trations (16.7 and 50 μM for DMF, 50 and 150 μM for MMF) were com-
pared and correlated to proﬁles of benchmark compounds in the
BioSeek library. Assay details and statisticswere as described previously
(Berg et al., 2006; Kunkel et al., 2004b).
Mean OD values for each parameter were calculated from triplicate
samples per experiment.
For the Benchmark Database comparisons, Pearson correlation coef-
ﬁcients were calculated between test compounds (at non-toxic, active
76 G.O. Gillard et al. / Journal of Neuroimmunology 283 (2015) 74–85doses) and compounds from BioSeek's database (3C, 4H, LPS and SAg
systems). Statistically signiﬁcant correlations were identiﬁed based on
comparisons of these true Pearson correlations to a set of Pearson corre-
lations obtained from randomizing the experimentally observed values.
2.2. HCS screening of translocation of p65 and p52
2.2.1. Reference compound validation of assay
The reference compound for TNF-induced p65 nuclear translocation
is 2-Amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-(4-
piperidinyl)-3-pyridinecarbonitrile (ACHP), a commercially available
IKKβ Inhibitor (Tocris Bioscience, Bristol, UK). The p52 translocation
assay was validated using BIO-032202, an in-house reference compound
based on a competitor's patented compound. All IC50 curves for ACHP and
BIO-032202 met acceptance criteria.
2.2.2. Dilution of fumarates
Compoundswere added to the cells 30min before stimulation. Eight
doses of the fumaric acid esters (DMF, MMF, and MEF) were tested: 18,
12, 6, 3, 1, 0.5, 0.25, and 0.125 μg/mL. In plates 3 and 4, dose–response
curves were tested in the presence of 3 μg/mL DMF or MMF.
2.2.3. Stimulation and assessment of p65 and p52 translocation
U-2 OS cells were stimulated with 10 ng/mL TNF-α for 30 min (p65
assay) or 10 ng/mL of the anti-lymphotoxin β receptor (LTβR) antibody
BS-1 for 4 h (p52 assay). The cells were then ﬁxed and stained with an
antibody that recognizes the appropriate protein. Images of each well
were acquired on the PerkinElmer Operetta and the images were ana-
lyzed using PerkinElmer Columbus Image Analysis software. All plates
had a Z′ score ≥0.5 and a signal-to-noise ratio of ≥5.
2.3. Ramos-Blue reporter assay
2.3.1. Culturing Ramos-Blue B lymphocyte cell line
Ramos-Blue cells were thawed from the manufacturer (InvivoGen)
and cultured in Ramos-Blue cell culture medium without the selective
antibiotic Zeocin. The cells were then passaged every 3–4 days in the
Ramos-blue cell culture mediumwith Zeocin at 100 μg/mL to a concen-
tration of 1 × 106 cells/mL, and never exceeding 6 × 106 cells/mL.
2.3.2. Dilution of DMF, MMF, and MEF
Compounds were prepared on a plate in DMSO at 15 μg/mL and se-
quentially diluted in order to generate the different fumarate stock con-
centrations in a standard volume of DMSO. This dilution plate was used
to make the ﬁnal dilution of 5× compound in Ramos-blue cell culture
media. This was done by adding 3 μl from each well (concentration) of
the dilution plate to a 1.7 mL microcentrifuge tube containing 997 μl
of cell culture media.
2.3.3. Pre-incubation of Ramos-Blue cells with DMF, MMF, and MEF
Ramos-blue cells were re-suspended in Ramos-Blue culturemedium
without Zeocin at a concentration of 2 × 106 cells/mL. 175 μl of cells was
added to the appropriate number of wells in a 96-well round bottom
plate. The wells were treated with 50 μl of the varying concentrations
of each compound from the dilution tubes. The wells were incubated
for 30 min at 37 °C and 5% CO2.
2.3.4. Activation of Ramos-Blue cells
Wells were treated with 25 μl of ODN 2006 at a ﬁnal working con-
centration of 10 μg/mL. For CD40-stimulated cells, agonistic anti-
human CD40 antibody clone G28.5 (Biolegend, Ultra-LEAF αCD40)
was added to a ﬁnal working concentration of 10 μg/mL. Isotype control
antibody (BioLegend; Ultra-LEAF mouse IgG1 κ, clone MOPC-21) was
used at equal concentration for unstimulated wells. The wells were in-
cubated for 24 h at 37 °C and 5% CO2.2.3.5. Detection of NF-κB activity through the production of secreted
embryonic alkaline phosphatase (SEAP)
Theplatewas centrifuged at 1800 rpm for 10min to pellet cells. 40 μl
of supernatant was taken from thewells and put into a new 96-well ﬂat
bottom plate. 200 μl of QUANTI-Blue reaction mixture, pre-warmed to
37 °C, was added to the wells. The wells were incubated at 37 °C for
75 min in the dark. The wells were read on a microplate reader using
a wavelength of 635 nm.
2.4. Cytokine responses in fumarate-treated primary splenocytes in
response to lipopolysaccharide (LPS) or CpG-B stimulation
2.4.1. Preparation of splenocytes
Primary splenocyteswere isolated from age-matchedNRF2−/−mice
or age-matched control wild-type (WT) mice. Splenocytes were recov-
ered via mechanical dissociation of spleens, followed by washing and
lysis of RBS (Sigma). Cells were then counted, centrifuged, and resus-
pended at 2 × 106 cells/mL in X-VIVO 10 (Lonza) chemically deﬁned
media and stored on ice.
2.4.2. Preparation of fumarate dilutions and working stocks
Stocks of fumarates for dilution series were at an initial concentra-
tion of 30 mg/mL in DMSO. Final concentrations to be tested were
9 μg/mL, 6 μg/mL, 3 μg/mL, and 1 μg/mL. Working stocks (4× ﬁnal con-
centration) of fumarateswere generated inX-VIVO 10media andmixed
well.
2.4.3. Preparations of working stocks of LPS, CpG-B ODN 2006, CpG-B ODN
1826, and controls
Stocks of LPS (Sigma-Aldrich, ion-exchange chromatography puri-
ﬁed from Escherichia coli strain 0111:B4) and CpG-B oligonucleotides
(1826 for murine cell stimulation and 2006 for human PBMC stimula-
tion; InVivoGen, San Diego, CA) were prepared at 40 ng/mL and
40 μg/mL, respectively, in X-VIVO 10media, to yieldﬁnal concentrations
of 10 ng/mL and 10 μg/mL, respectively; 2 replicates per condition with
no stimulation (vehicle control for each fumarate condition). Wells re-
ceiving vehicle (PBS) received 6 μg/mL (ﬁnal concentration) of
fumarates.
2.4.4. Preparation of plates
For each plate, 50 μl of fumarate/DMSO control working stock were
added, followed by 50 μl of stimulation mix, followed by 100 μl of cells
at 2 × 106 cells/mL. Combination ofworking stocks and cells in ﬁnal vol-
ume of 200 μl/well result in the desired ﬁnal concentrations of fuma-
rates (9, 6, 3, 1, 0 μg/mL) and stimuli (10 ng/mL for LPS and 10 μg/mL
for CpGs). Plates (2 plates per stimulus) were then transferred into
37 °C incubator and supernatants were harvested 24 h later and trans-
ferred to new 96 well plates that were immediately placed in−80 °C.
2.4.5. Quantiﬁcation of cytokine/chemokine in cell culture supernatants
The Milliplex Magnetic multiplex mouse cytokine/chemokine
magnetic premixed bead immunoassay (premixed 25-plex; Cat #
MCYTOMAG-70 K-PMX) was used to quantify cytokine levels in tissue
culture supernatants in direct accordance with the manufacturer's pro-
tocol. Freshly thawed tissue culture supernatant (25 μl) was assayed in
duplicate. All plates were run with overnight incubation of sample and
beads at 4 °C with shaking. After washing and resuspension, beads
were read on either a Luminex 100 reader or a Luminex 200 reader.
3. Results
3.1. DMF and MMF show signiﬁcant overlap in activity proﬁles in BioMAP
assays but marked differences in potency
Given that numerous cellular pathways are affected by fumarates,
we began our study with a systematic screen for similarities and
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Fig. 1. BioMAP proﬁles for DMF and MMF. BioMAP proﬁles of DMF (A) and MMF (B), tested at multiple concentrations in 7 BioMAP systems. The biomarker readouts measured (see the
Materials andmethods section) are indicated along the x-axis. The y-axis shows the log10 expression ratios of the readout level measurements relative to solvent (DMSObuffer) controls.
Each datapoint represents a single well. The gray area above and below the dashed line indicates the 95% signiﬁcance envelope of DMSO negative controls. The BioMAP proﬁles for DMF
and MMF at a standard concentration of 50 mM are plotted in C.
77G.O. Gillard et al. / Journal of Neuroimmunology 283 (2015) 74–85differences between DMF and MMF using the BioMAP® system. The
BioMAP® analysis system consists of 7 individual assays that use com-
plex co-cultures of primary human cells to model the effects of testedTable 2
Reproducibility between two repeat BioMAP experiments.
Compound Dose Pearson correlation across seven BioMAP systems
DMF 150 μM (toxic) 0.87
DMF 50 μM 0.95
DMF 16.7 μM 0.86
MMF 450 μM (toxic) 0.93
MMF 150 μM 0.83compounds on cell intrinsic-responses and diverse cell–cell interactions
(Kunkel et al., 2004a,b). The effects of tested compounds are read out
using multiple parameters for each of the seven assays. Additional de-
tails on the seven individual assays and the readouts for each assay
can be found in Supplemental Table 1. The combined biological effects
of a compound on each analyte in each assay are used to generate an ac-
tivity proﬁle for the compound. The activity proﬁle of a compound ob-
served in BioMAP® systems can be used to identify molecules and
pathways that are affected by a given compound, and can also be
compared (“benchmarked”) against a database of activity proﬁles of
hundreds of experimental drugs and approved therapeutics. This
“benchmarking” provides insight into the mechanism of action or
Table 3
Benchmarking hits in BioSeek database identify DMF andMMF as NF-kB-pathwaymodulators. DMF andMMF proﬁles at non-toxic doseswere compared to proﬁles in the BioSeek Bench-
mark Database as described in Appendix I. Compoundswith signiﬁcantly related proﬁles (FDR b 0.05) are listed. The correlation coefﬁcients (r) for the pairwise comparisons are shown for
all four systems, and for individual systems.
r (individual systems)
Compound Database Match Mechanism r FDR LPS 3C SAG 4H
DMF (50 μM) Ro106-9920 (5.5 μM) IkBα ubiquitination inhibitor 0.820 0.012 0.960 0.926 0.362 0.936
BAY 11-7085 (2.7 μM) IkBα phosphorylation inhibitor 0.782 0.012 0.954 0.900 0.569 0.852
Parthenolide (3.7 μM) NF-κB inhibitor (p65 alkylation) 0.768 0.012 0.755 0.950 0.500 0.664
GW8510 (8.3 μM) CDK inhibitor 0.805 0.014 0.936 0.772 0.884 0.988
Roscovitine (25 μM) CDK inhibitor 0.666 0.063 0.669 0.766 0.312 0.915
DMF (16.7 μM) Ro106-9920 (1.8 μM) IkBα ubiquitination inhibitor 0.847 0.009 0.852 0.726 0.874 0.973
Ro106-9920 (5.5 μM) IkBα ubiquitination inhibitor 0.773 0.012 0.546 0.958 0.893 0.968
BAY 11-7085 (0.9 μM) IkBα phosphorylation inhibitor 0.842 0.009 0.860 0.801 0.973 0.713
BAY 11-7085 (2.7 μM) IkBα phosphorylation inhibitor 0.833 0.009 0.694 0.983 0.964 0.902
Parthenolide (3.7 μM) NF-κB inhibitor (p65 alkylation) 0.781 0.012 0.691 0.778 0.932 0.886
MMF (150 μM) Roscovitine (8.3 μM) CDK inhibitor 0.702 0.011 0.731 0.930 0.960 0.832
Olomoucine (33 μM) CDK inhibitor 0.697 0.011 0.672 0.772 0.887 0.848
BAY 11-7085 (0.9 μM) IkBα phosphorylation inhibitor 0.678 0.021 0.641 0.862 0.805 0.631
BAY 11-7085 (2.8 μM) IkBα phosphorylation inhibitor 0.665 0.021 0.497 0.881 0.871 0.858
Ro106-9920 (1.8 μM) IkBα ubiquitination inhibitor 0.675 0.021 0.695 0.735 0.611 0.899
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et al., 2004a,b).
DMF and MMF were tested in 7 BioMAP® model systems at seven
doses starting at 150 μM (DMF) or 450 μM (MMF) with threefold dilu-
tions. DMF and MMF were active in all 7 BioMAP® systems (Fig. 1).
DMF was active between 5.5 and 50 μM (IC50 ~ 30 μM) and showed
signs of cellular toxicity at 150 μM (Fig. 1A). MMF was active between
50 and 150 μM (IC50 ~ 190 μM) and was toxic at 450 μM (Fig. 1B).
DMF and MMF exhibited similar BioMAP® proﬁles but at distinctly dif-
ferent doses. Mechanistic clustering across multiple doses showed the
best correlation between the 16.7 μM DMF and 150 μM MMF doses
(compare Fig. 1A and B) suggesting that the two compounds generate
similar responses in these assays, albeit with different potencies. This
is highlighted in Fig. 1C, where DMF and MMF are compared directly
at 50 μM. While direct dose and tissue exposure is difﬁcult to deter-
mine, the plasma concentration of MMF falls in a range between 10
and 40 μM in vivo after an oral dose of 240 mg DMF (Litjens et al.,
2004a,c). BioMAP proﬁles showed statistically signiﬁcant inhibition
of VCAM-1 and E-selectin (but not ICAM-1) expression, in agree-
ment with ﬁndings in psoriasis patients in vivo (Loewe et al.,
2001). Additional markers affected by DMF andMMF, which fall out-
side the 99.7% prediction envelope, included HLA-DR, Eotaxin-3,BA
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BioMAP activity proﬁles across the seven systems were highly repro-
ducible, with a Pearson correlation between the two replicate exper-
iments ranging from 0.83 to 0.95 (Table 2).
Statistical comparison of the DMF and MMF proﬁles (3C, 4H, LPS,
SAg) with the proﬁles of compounds in the BioSeek database resulted
in two types of hits: inhibitors of NF-κB signaling and cyclin-
dependent kinase (CDK) inhibitors (Table 3). The NF-κB inhibitor
group includes Ro106-9920, BAY 11-7085, and parthenolide. These
hits suggest that DMF and MMF inhibit the NF-κB pathway at the level
of the NF-κB/IκB complex, in agreement with published studies
(Loewe et al., 2001; Vandermeeren et al., 2001). However, the differ-
ence in potency between DMF and MMF is profound.
The NF-κB pathway is a pivotal regulator of innate and adaptive im-
munity, and its dysregulation is implicated in the chronic inﬂammation
of autoimmune diseases. Given the published studies on fumaratemod-
ulation of NF-κB signaling (Cross et al., 2011; Gerdes et al., 2007;
Ghoreschi et al., 2011; Kim et al., 2010; Lee et al., 2009; Loewe et al.,
2001, 2002; Lv et al., 2013; Peng et al., 2012; Vandermeeren et al.,
2001) and the differences we saw between potency of DMF and MMF0
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impacts on NF-κB signaling.3.2 DMF inhibits expression of an NF-κB-responsive reporter gene
DMF has been shown to inhibit NF-κB-mediated cellular responses
(Gerdes et al., 2007; Ghoreschi et al., 2011; Kim et al., 2010; Lee et al.,
2009; Loewe et al., 2001, 2002; Lv et al., 2013; Peng et al., 2012;
Vandermeeren et al., 2001). We sought to determine if MMF or MEF
also inhibit NF-κB activity. Ramos-Blue cells, which harbor an NF-κB-
inducible secreted embryonic alkaline phosphatase (SEAP) reporter
gene, were stimulated with CpG-B or an agonistic anti-CD40 mAb.
Toll-like receptor (TLR)9 stimulation (via CpG) activates canonical NF-
κB signaling and CD40 agonism activates canonical and non-canonical
NF-κB signaling (Kawai and Akira, 2006; Razani et al., 2011; Shih
et al., 2011; Sun, 2012). DMF, but not MMF or MEF, inhibited NF-κB re-
porter activity in a dose-dependentmanner under both CpG-B and anti-
CD40 stimulation (Fig. 2).3.3 DMF inhibits pro-inﬂammatory cytokine production by primarymurine
splenocytes
Having determined that DMF, but not MMF or MEF, signiﬁcantly
inhibited NF-κB activity in a reporter cell line, we next assessed whether
these fumarates impacted the production of NF-κB-driven pro-
inﬂammatory cytokines in primary immune cells. Primary splenocytes
isolated from C57BL/6 mice were stimulated with LPS or CpG-B in the
presence of DMF, MMF, or MEF. Cell culture supernatants were collected
at 24 h and IL-6, IP-10, and MIP-1βwere assayed. DMF, but not MMF or
MEF, signiﬁcantly reduced the levels of IL-6, IP-10, and MIP-1β after
stimulation with LPS (Fig. 3A) or CpG-B (Fig. 3B) in a dose-dependent
manner.3.4 DMF inhibits pro-inﬂammatory cytokine production by human PBMCs
We next wanted to determine if DMF-mediated NF-κB inhibition is
consistent between mouse and human primary cells. Freshly isolated
human peripheral blood mononuclear cells (PBMC) were stimulated
with LPS or CpG-B in the presence of DMF, MMF orMEF. Cell culture su-
pernatants were collected at 24 h and IL-6, IP-10 and MIP-1β were
assayed. DMF, but not MMF or MEF, signiﬁcantly reduced the levels of
IL-6, IP-10, and MIP-1β after stimulation with LPS (Fig. 4A) or CpG
(Fig. 4B) in a dose-dependent manner. These results demonstrate that
the mechanistic impact of DMF on NF-κB-driven pro-inﬂammatory cy-
tokine production is conserved between mouse and human.3.5 DMF inhibits nuclear translocation of NF-κB signaling subunits p65 and
p52
While stimulation of immune cells through TLRs activates canonical
NF-κB signaling (Kawai and Akira, 2006), non-canonical NF-κB signal-
ing also plays an important role in immune cell activation (Razani
et al., 2011; Sun, 2012). Therefore, we wanted to determine the impact
of different fumarates on canonical versus non-canonical NF-κB signal-
ing at the molecular level. Canonical activation of NF-κB is mediated by
an IκB kinase (IKK) complex consisting of IKKα and IKKβ that phos-
phorylate the inhibitor IκB, resulting in the release of p65/p50 dimers
that translocate to the nucleus and stimulate gene transcription at tar-
get sites (Shih et al., 2011). Alternatively, activation of NF-κB-inducing
kinase (NIK) causes processing of p100, resulting in the release and nu-
clear translocation of p52/relB dimers (Razani et al., 2011; Sun, 2012).
To determine if DMF directly inhibits NF-κB at the molecular level,
we assessed nuclear translocation of the signaling subunits of the ca-
nonical (p65) and non-canonical (p52) NF-κB pathway using a high
content screen. Human osteosarcoma OS-2 cells were stimulated for
30 min with TNFα (canonical stimulus) or an agonistic lymphotoxin
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Fig. 4.DMF, but not other fumarates, inhibits NF-κB-dependent cytokine responses by primary human PBMC in vitro. Production of IL-6, IP-10, andMIP-1β by Ficoll-puriﬁed human PBMC
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ence of DMF,MMF orMEF. Cells were then ﬁxed, permeabilized, stained
for p65 or p52 and imaged. Nuclear translocation was assessed by auto-
mated image analysis, and results are shown as percent inhibition based
on stimulated DMSO-treated controls. Representative images of p65
translocation (Fig. 5A) and p52 translocation (Fig. 5B) are shown with
negative control (unstimulated, DMSO control), positive control (stim-
ulated, DMSO control) and DMF treatment (stimulated, 18 μg/mL
DMF). DMF, but not MMF or MEF, inhibited p65 and p52 nuclear trans-
location in a dose-dependent manner (Fig. 5C, D), demonstrating a di-
rect effect on both canonical and non-canonical NF-κB signaling.
3.6 DMF inhibition of NF-κB-mediated cytokine release is independent of
Nrf2
DMF is able to stimulate the antioxidant response pathway via Nrf2
activation, which may inﬂuence pro-inﬂammatory cytokine production
(Lv et al., 2013). There is also experimental evidence of crosstalk between
the KEAP1-Nrf2 pathway and NF-κB signaling (Cross et al., 2011;
Cuadrado et al., 2014; Ghoreschi et al., 2011; Kim et al., 2010; Lee et al.,
2009; Lv et al., 2013; Peng et al., 2012; Yu et al., 2011). Thus, we wanted
to determine if the effect of DMF onNF-κB-mediated cytokine production
was Nrf2-dependent. Primary splenocytes from WT and Nrf2−/− mice
were stimulated with LPS or a TLR9 agonist, CpG-B for 24 h and cell cul-
ture supernatantswere assayed for a panel of cytokines. Aswe previously
observed,DMF, but notMMForMEF, signiﬁcantly reduced theproduction
of IL-6, IP-10, and MIP-1β in WT C57BL/6 splenocytes in a dose-
dependent manner (Fig. 6A–B). The impact of DMF was maintained in
splenocytes from Nrf2−/−mice, demonstrating that the impact of DMF
on NF-κB-mediated cytokine production is Nrf2-independent.
In addition to IL-6, IP-10, and MIP-1β, DMF treatment (9 μg/mL) led
to signiﬁcant inhibition of numerous other cytokine analytes (Fig. 7).
Following LPS stimulation, DMF treatment signiﬁcantly reduced the
production of 13 analytes (G-CSF, GM-CSF, IL-1β, IL-6, IP-10, IL-10,
TNFα, MCP-1, MIP-1α, MIP-1β, MIP2, KC, and RANTES; (all p b 0.05 orp b 0.01)) by WT splenocytes. In the remaining 12 analytes, 11/12
were below the lowest limit of quantitation. Therewas reduced produc-
tion of IL-9 relative to vehicle control; however, this result did not
achieve statistical signiﬁcance (p = 0.169).
The ability of DMF to reduce secretion of these cytokines was com-
parable in both WT (top graph) and Nrf2−/− (bottom graph)
splenocytes (Fig. 7A). DMF treatment signiﬁcantly reduced production
of 16 analytes (G-CSF, GM-CSF, IL-1β, IL-6, IP-10, IL-10, IL-12p70, IL-
13, IFNγ, TNFα, MCP-1, MIP-1α, MIP-1β, MIP2, KC, and RANTES; (all
p b 0.05 or p b 0.01)) by Nrf2−/− splenocytes; in the remaining 9
analytes, 8/9 were below the lowest limit of quantitation. There was re-
duced production of IL-9 relative to vehicle control; however, this result
did not achieve statistical signiﬁcance (p = 0.095).
Following CpG stimulation, DMF treatment signiﬁcantly reduced the
production of 12 analytes (G-CSF, GM-CSF, IL-1α, IL-1β, IL-6, IL-9, IP-10,
KC, MCP-1, MIP-1α, MIP-1β, and RANTES; (all p b 0.05 or p b 0.01)) by
WT splenocytes. For the remaining 13 analytes, 7/13 were below the
lowest limit of quantitation. We observed reduced production of TNFα
(p = .094), IL-5 (p = .087), IL-10 (p = .051), IL-12p70 (p = 0.101),
IL-13 (p = 0.214), and IL-15 (p = 0.243) relative to vehicle control;
however, these results did not achieve statistical signiﬁcance.
The ability of DMF to reduce secretion of these cytokines in response
to CpG stimulation was comparable in both WT (top graph) and
Nrf2−/− (bottom graph) splenocytes (Fig. 7B). DMF treatment signiﬁ-
cantly reduced production of 15 analytes (GM-CSF, IL-2, IL-5, IL-6, IL-
10, IL-12p70, IL-13, IL-15, IP-10, IFNγ, KC, MCP-1, MIP-1α, MIP-1β,
and RANTES (all p b 0.05 or p b 0.01)) by Nrf2−/− splenocytes; 4 of
the remaining 10 analytes were below the lowest limit of quantitation.
We observed reduced production of G-CSF (p = 0.079), IL-1a (p =
0.058), IL-1b (p = 0.108), and IL-9 (p = 0.095) by DMF-treated versus
DMSO-treated Nrf2−/− splenocytes; however, these results did not
achieve statistical signiﬁcance.
In summary, DMF, but not MMF or MEF, reduced production of a
broad range of pro-inﬂammatory cytokines by LPS- and CpG-stimulated
splenocytes in an Nrf2-independent manner.
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It has long been recognized that fumarates are potent therapeutic
compounds that exert pleiotropic immunomodulatory effects. Multiple
pathways have been implicated in mediating these effects, from strong
potentiation of theNrf2 pathway for cytoprotective and anti-oxidant re-
sponses, to the anti-inﬂammatory effects downstream of HCA2 signal-
ing, to direct inhibition of NF-κB pathway activation. The degree to
which each of a variety of individual fumarate esters can impact the in-
volved pathways differentially has yet to be deﬁned, and is complicated
by signiﬁcant variation in the tissue exposure levels, absorption rate,
and rate of metabolism for each of the various compounds. DMF, for in-
stance, has highest penetrance in gut, and the vast majority is rapidly
transformed in vivo by either being metabolized into MMF or by
forming conjugates with glutathione. The degree to which each form
contributes to the overall immunomodulatory effect in vivo is unclear;
however, the fact that DMF, MMF, and MEF exhibit differential effects
in some models suggests that the differences between these fumarates
have signiﬁcant biological consequences.
In the present study, we investigated the ability of fumarates to
modulate a range of cellular pathways. Statistical comparison of the
DMF andMMF proﬁles with proﬁles of other compounds in the BioSeek
Benchmark database showed strong correlation with known inhibitors
of NF-κB signaling. These NF-κB inhibitors include Ro106-9920, BAY
11-7085, and parthenolide. Ro106-9920 inhibits phosphorylated IκBα
ubiquitination and subsequent degradation, presumably by direct inhi-
bition of an E3 ubiquitin ligase (Lee et al., 2009; Swinney et al., 2002).
BAY 11-7085 irreversibly inhibits the phosphorylation of IκBα (Pierce
et al., 1997). Parthenolide, a plant-derived sesquiterpene lactone, alkyl-
ates the p65 subunit of the NF-κB complex, inhibiting DNA binding
(Garcia-Pineres et al., 2004). Parthenolide may also inhibit IκB kinasesthrough a covalent modiﬁcation (Kwok et al., 2001). These consistent
BioSeek proﬁles suggest that one of the potential mechanisms of action
for DMF andMMF is to inhibit NF-κB pathway at the level of the NF-κB/
IκB complex, in agreement with published studies (Loewe et al., 2002;
Vandermeeren et al., 2001).
Based on this strong correlation between DMF andMMF and known
NF-κB inhibitors,we chose to focus on the ability of various fumarates to
modulate NF-κB-driven cellular responses. Dysregulation of the NF-κB
pathway is a cardinal feature in the chronic inﬂammation observed in
the context of autoimmune diseases. The results of these studies are
quite striking: in all assays, treatment with DMF, but not equivalent
doses of MMF or MEF salts, inhibited NF-κB-dependent responses.
Treatment with DMF, but not MMF or MEF salts, led to reduced expres-
sion of NF-κB-dependent gene activity in a reporter cell line. Treatment
of murine or human primary cell cultures with DMF, but not MMF or
MEF salts, resulted in signiﬁcant reduction in cytokine production
after stimulation via the canonical and non-canonical NF-κB stimuli, in
a dose-dependent fashion. The effect of DMF on NF-κB-dependent re-
sponses was conﬁrmed to be a direct effect on NF-κB signaling, as
DMF treatment resulted in signiﬁcant inhibition of the nuclear translo-
cation of the p65 (canonical/classical NF-κB) and p52 (non-canonical
NF-κB) signaling in a high content screening assay.
Many of the effects of fumarates have been attributed to the ability
of these molecules to stimulate the anti-oxidant response through en-
hancing the level and activity of the transcription factor Nrf2. Nrf2 activ-
ity is regulated at the molecular level by KEAP1. KEAP1 sequesters and
poly-ubiquitinates Nrf2 in the cytosol, leading to constitutive degrada-
tion (Nguyen et al., 2009). Electrophilic and oxidative stress changes
the interaction between Nrf2 and KEAP1, resulting in the stabilization
and translocation of Nrf2 to the nucleus. Similarly, DMF interaction
with KEAP-1 results in the stabilization and translocation of Nrf2.
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Nrf2 pathway and NF-κB signaling. Lee et al. demonstrated that KEAP1
binds IKKβ and mediates ubiquitination and subsequent degradation
(Lee et al., 2009). Depletion of KEAP1 led to an increase in NF-κB signal-
ing. A separate study demonstrated that genetic knockdown of KEAP1
led to enhanced IL-6 production, an NF-κB target gene, in LPS-
stimulated macrophages. Interestingly, we demonstrate in our study
that DMF treatment inhibited pro-inﬂammatory cytokine production
by culturedWT and Nrf2−/− splenocytes with equal efﬁciency, demon-
strating that the ability of DMF to suppress NF-κB dependent responses
was independent of Nrf2 activity.
These results demonstrate that equivalent amounts of DMF, MMF,
and MEF salts display distinct abilities to inﬂuence immune responses
via the NF-κB pathway in these assays. As mentioned previously, DMF
is rapidly metabolized to MMF (its primary metabolite) and also forms
glutathione adjuncts. Based on the metabolism and pharmacokinetics
of DMF it is impossible to know the in vivo targets and local tissue expo-
sure of DMF. The assumption has been that signiﬁcant direct exposure
to unmodiﬁed/unmetabolized DMF is limited to a small population of
cells and that consequently, the therapeutic effects of DMF aremediated
by its primary metabolite MMF. As a consequence, preclinical studies
have traditionally used DMF and MMF interchangeably both in vitro
and in vivo. However, this assumption isﬂawed, as the tissue concentra-
tion and target cell exposure toMMF in vivo is not known, and therefore
it is difﬁcult to draw meaningful parallels between in vitro and in vivo
active concentration for MMF. In the absence of knownMMF target tis-
sue concentrations for modeling the effects of fumarates, we based the
range of concentrations used in our NF-κB-driven assays on the report-
ed concentration range for MMF in the plasma of patients, where MMF
concentration has been measured in a range from 1 to 5 μg/mL (≈10–
40 μM) (Litjens et al., 2004a; Sheikh et al., 2013). The highest dose we
used in our cytokine production assays, 9 μg/mL, corresponds to an ap-
proximate concentration of 60 μM for DMF and 70 μM for MMF. Based
on the assumption that the range of concentrations used approximates
the plasma concentration of MMF in patients, the differential fumarate
effects on NF-κB activity observed may well represent effects at a
more “physiological” concentration. The BioSeek proﬁles for DMF and
MMF indicate that these concentrations fall well below toxicity level
for both compounds but reﬂect a signiﬁcant difference in potency be-
tween the two compounds for modifying NF-κB-driven responses, as
DMF had an IC50 of approximately 30 μM versus 190 μM for MMF. The
pharmacokinetics and serum concentration of MEFs in vivo is similar
to that of MMF, not DMF, so at similarly “physiological” concentrations
of MEFs, we did not observe any inhibition of NF-κB-driven responses.
That we did not observe any signiﬁcant effect of MMF or MEF on NF-
kB-driven responses at these levels suggests that perhaps a signiﬁcant
component of the therapeutic beneﬁt of fumarates is mediated by ef-
fects on cells and tissues that either have direct exposure to DMF or ex-
perience very high local concentrations of MMF and MEF.
In this study, we have directly compared the activity of DMF and
MMF.We observed signiﬁcant differences between the biological activ-
ities of these two closely related, yet distinct compounds. In addition,
the inclusion of MEF salts without DMF also allowed us to separate
the activity of MEF salts on NF-κB-driven cytokine production from
those mediated by DMF. These results establish that DMF is the most
potent fumarate tested for modulating NF-κB signaling. The differential
effects we observed on NF-κB-dependent responses were largely Nrf2-
independent, despite the well-established role for Nrf2 in fumarate-
mediated cellular responses. This suggests that the impact that fuma-
rates exert on cellular responses is mediated by the integration of
their effects on multiple and distinct pathways, each of which may be
differentially affected depending on which fumarate is present. While
DMF may be more effective than MMF or MEF salts at modulating NF-
κB-driven responses, as these data indicate, the activation of Nrf2, the
modulation of the glutathione system, or the activation of GPR109A
may all be mediated differentially depending on whether the cellshave been exposed to DMF, MMF, or MEF salts. In that vein, it is impor-
tant to note that MMF is a signiﬁcantly more potent activator of the
HCA2 pathway (70 nM) than DMF (N10 μM) (Tang et al., 2008), and
that concentration of MMF falls well within the plasma exposure levels
for MMF observed after patients receive a 240 mg dose of delayed-re-
lease DMF (Cmax of 1–3 μg/mL MMF in plasma) (Sheikh et al., 2013).
Given the common pharmacodynamic observation of ﬂushing in de-
layed-release DMF clinical trials (Fox, 2012; Fox et al., 2014; Gold,
2011; Kappos et al., 2008, 2012), and the role of HCA2 in mediating
these responses (Hanson et al., 2010, 2012), it seems likely that there
is activation of this receptor in patients taking delayed-release DMF. Al-
thoughMMF andMEF were not active in modulating inﬂammatory NF-
κB-related responses in the assays described here, given the emerging
role of HCA2 in regulating macrophage function it is likely that MMF
and MEF exert other immunomodulatory activities that need to be
more fully explored (Chen et al., 2014; Hanson et al., 2010, 2012; Tang
et al., 2008).
Additional studies will be necessary to further explore potential dif-
ferential effects of these compounds and identify their relative contribu-
tions to the various biological activities attributed to fumarates.
Understanding how each fumarate impacts these various biological
pathways relative to one another will be crucial to understanding the
contributions these compounds make to the therapeutic effects ob-
served in patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jneuroim.2015.04.006.Disclosures
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